Clinical trial NCT06775496: Life-threatening Infection in Humans: from Epidemiological Analysis to Molecular Genetics
Official title: Life-threatening Infection in Humans: from Epidemiological Analysis to Molecular Genetics
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Life-threatening Infection
Lead sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
Sponsor class: OTHER
First posted: 2025-01-15
Enrollment: 360
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Will be enrolled, patients evaluated or admitted, at the O.U. Department of Emergency Pediatrics, Emergency Room and Short and Intensive Observation, the Immunology Outpatient Clinic of the O.U. of Infectious Diseases, the U. O. Anesthesiology and General and Pediatric Resuscitation, of Neonatology and Neonatal Intensive Care, belonging to the IRCCS AOUBO, and the U.O.C. of Pediatric Neuropsychiatry of the IRCCS Institute of Neurological Sciences in Bologna.

Brief summary: This study, aims to identify and calculate the prevalence of cases potentially associated with congenital errors of immunity (ECI) among patients, hospitalized with infectious disease and carry out their clinical-laboratory characterization. Diagnoses of ECI are becoming increasingly common, by virtue of the continuing discoveries of new disease-causing genes and an increasing understanding of the clinical signs and symptoms of these entities.

The most important challenge still remains to achieve early diagnosis, which is essential for appropriate and individualized treatment that also takes into account the prognostic and genetic counseling aspect related to these disorders, which are associated with high rates of morbidity and mortality.

Patients with nonimmunological diseases, secondary immunodeficiencies, nonpharmacological iatrogenic factors, and immunosuppressive drug therapies will be involved in the study.

Detailed description: Severe, up to potentially fatal infections , represent a frequent cause of hospitalization in various clinical settings (pediatric and adult). Any infection of bacterial, viral, mycobacterial, or fungal etiology with a severe course, whether systemic (e.g., sepsis or septic shock, disseminated intravascular coagulation) or focal (e.g., pneumonia, meningitis, encephalitis skin infection) that causes organ damage and/or requires organ-specific or intensive supportive treatment (mechanical ventilation, inotropes, renal replacement treatment) should be considered life-threatening.

Eligibility criteria: Inclusion Criteria:

* Obtained informed consent;
* Otherwise healthy patient on admission

Infectious episode:

* life-threatening caused by known or unknown etiologic agent including viruses, bacteria, mycobacteria or mycetes (in case of lack of microbiologic isolate if clinical, laboratory, histopathologic and radiologic data, justify an infectious origin)
* or caused by vaccine strains of attenuated vaccines such as Measles, Mumps, Rubella, Yellow Fever.
* or caused by viruses, bacteria, mycobacteria or mycetes with features suggestive of congenital deficiency of immunity, the clinical pictures below refer to known conditions potentially associated with congenital errors of innate immunity

Viral susceptibility:

* ARDS caused by influenza virus type A, Sars-Cov2
* Life-threatening enterovirus rhomboencephalitis
* Life-threatening infection by VZV, CMV, EBV, Rhinovirus, Respiratory Syncytial Virus
* HSV encephalitis
* Fulminant hepatitis from HAV
* Kaposi\&#39;s sarcoma from HHV8
* Beta-HPV infections such as: epidermodysplasia verruciformis, mucocutaneous carcinoma,recurrent/diffuse skin warts,, papillomatosis.

Susceptibility to pyogenic bacteria:

* At least one life-threatening infection or two episodes of invasive infectionsin otherwise healthy patients, either systemic (bacteremia) or focal (pneumonia, meningitis, arthritis, osteomyelitis, deep brain/peritoneal/hepatosplenic/muscle abscesses)
* At least two episodes of disseminated or severe staphylococcal muco-cutaneous infections in otherwise healthy patients: decalvant folliculitis, pustules, furunculosis, blepharitis, lymphadenitis, abscesses

Susceptibility to Tropherymawhipplei:

- Whipple\&#39;s disease

Susceptibility to Mycobacteria:

* Life-threatening , recurrent, or persistent infections with tuberculous or nontuberculous mycobacteria in otherwise healthy patients
* Post-vaccinal BCG-osis from attenuated M. Bovis strain

Susceptibility to mycetes:

* Chronic muco-cutaneous candidiasis Invasive fungal infections of sinuses, lungs, CNS, bones, joints, liver, spleen, and mucocutaneous membranes by Coccidioides, Paracoccidiodes, Cryptococcus, Histoplasma, Pneumocystis, Aspergillus, Talaromyces, Mucormycetes, or Blastomyces
* Invasive candidiasis of brain, eyes, heart, bone, and blood in the absence of central catheters
* Blood dissemination of fungal pathogens (except for candidiasis from central access)
* Persistent positive fungal culture after adequate therapy in terms of drug susceptibility, dosage and duration
* Deep infection with dermatophytes (Microsporum, Epidermophyton, Tricophyton) at dermal and lymph node level
* Infection with rare yeasts (Geotrichum, Kodamaea, Malassezia/Rhodotorula, Saccharomyces, Trichosporon) or rare molds (AureobasidiumChrysosporium, Corynesprora, Exophiala, Geosmithia, Ochroconis, Paecilomyces, Phellinus, Phialophora, Rhizopus, Scopulariopsis)

Other:

-All infectious diseases not included in the list whose natural history differs from that expected for the identified pathogen with regard to severity, recurrence, and persistence of the disease, if the condition is not otherwise explainable by the patient\&#39;s acquired risk factors.

Exclusion Criteria:

* Patients with nonimmunological diseases, secondary immunodeficiencies, nonpharmacological iatrogenic factors, immunosuppressive drug therapies

Primary outcomes:
measure: Identification and Prevalence of cases potentially associated with ECI
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Bologna
country: Italy
facility: IRCCS Istituto delle Scienze Neurologiche
city: Bologna
country: Italy
facility: IRCCS Azienda Ospedaliero Universitaria di Bologna UO Pediatria
city: Bologna
country: Italy
facility: IRCCS Azienda-Ospedaliero Universitaria di Bologna UO Anestesiologia e Rianimazione generale e pediatrica
city: Bologna
country: Italy
facility: IRCCS Azienda-Ospedaliero Universitaria di Bologna UO Malattie Infettive
city: Bologna
country: Italy
facility: IRCCS Azienda-Ospedaliero Universitaria di Bologna UO Neonatologia e terapia intensiva neonatale
city: Bologna
country: Italy
facility: IRCCS Azienda-Ospedaliero Universitaria di Bologna UO Pediatria d'Urgenza, Pronto Soccorso e Osservazione Breve e Intensiva
Study officials:
affiliation: IRCCS Azienda Ospedaliero-Universitaria di Bologna
name: Daniele Zama, MD
role: PRINCIPAL_INVESTIGATOR
References: